We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020

By LabMedica International staff writers
Posted on 06 Feb 2020
Scope Fluidics Group (Warsaw, Poland) presented its new PCR|ONE system at MEDLAB Middle East, one of the world’s major events in the field of medical diagnostics that was held in Dubai World Trade Center and attended by thousands of visitors from over 135 countries.

New technology and the latest innovations in laboratory medicine were the main focus of the inaugural Transformation Talks, taking place at MEDLAB Middle East held from February 3-6, 2020. More...
In line with the show’s theme of Transforming tomorrow’s diagnostics, a range of new features were added to the 2020 edition of MEDLAB Middle East, including the Transformation Hub, where manufacturers had the opportunity to pitch their healthcare solutions to thousands of distributors.

Scope Fluidics introduced the PCR|ONE system to the participants of Transformation Talks at this year’s MEDLAB. The PCR|ONE is a 15-minute Point-Of-Care PCR for screening and syndromic testing that offers the world’s most rapid detection of bacteria and viruses – up to 20 different pathogens and drug resistance genes. The system is designed to analyze samples taken from a single patient in as little as 15 minutes, while its compact size makes it suitable for use in almost any medical practice or hospital admissions room.

“Technology is truly transforming medical diagnostics and healthcare and we are excited to take part in this process and contribute to faster and better access to information. This access to information is key to effective treatment because information allows for better formation of decisions. It saves lives and increases the comfort of patients and, ultimately, helps to reduce healthcare costs,” said Prof. Piotr Garstecki, CEO and Founder of Scope Fluidics Group. “The search and destroy policy urgently requires a rapid, accessible, and affordable diagnostic method than can be used in various settings. We believe PCR|ONE meets this crucial global need for a single-step method for rapidly and inexpensively identifying MRSA directly from nasal swabs.”

Related Links:
Scope Fluidics Group


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Hematology Consumables
Bioblood Devices
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.